Article Details
Retrieved on: 2022-06-08 15:09:19
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
It made sense to bring Astrazeneca on board three years ago because of the resources needed to develop Enhertu and datopotamab deruxtecan, ...
Article found on: www.evaluate.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here